(Boursier.com) — Regenerate , the American biotechnology firm, a partner in particular of Sanofi, published very strong growth in the fourth quarter. Revenue soared 104% to $4.95 billion, including $2.3 billion attributable to the drug Regen-Cov. Revenue outside of this treatment increased by 17% compared to last year. Annual revenues increased by 89% to 16.1 billion dollars (+19% excluding Regen-Cov). For the fourth quarter, GAAP earnings per share were $19.69 and adjusted diluted EPS was $23.72. The consensus was around $18 adjusted EPS for $4.47 billion in revenue.
©2022 Boursier.com